• 1
    Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Wanek LA, Chang C, et al. Prolongation of long-term survival in advanced stage metastatic melanoma following active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 46382.
  • 2
    Hellstrom KE, Hellstrom I, Morton DL, Hoon DSB, Foshug LJ, Nizze AJ, et al. Melanoma vaccines. In: BalchCM, HoughtonAN, MiltonGW, SoberAJ, SoongS-j, editors. Cutaneous melanoma. Philadelphia: JB Lippincott, 1992: 54259.
  • 3
    Morton DL, Foshag LJ, Nizze AJ, Gupta RK, Famatiga E, Hoon DSB, et al. Active specific immunotherapy in malignant melanoma. Semin Surg Oncol 1989; 5: 420425.
  • 4
    Berd D, Maguire HC, Jr, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46: 25727.
  • 5
    Livingston PO, Albino AP, Chung TJC, Francisco XR, Houghton AN, Oettgen HF, et al. Serological response of melanoma patients to vaccine prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 1985; 55: 71320.
  • 6
    Hanna MG Jr, Hoover HC Jr, Peters LC, Key ME, Haspel MV, McCabe RP, et al. Fundamental and applied aspects of successful active specific immunotherapy of cancer. In: OldhamRK, editor. Principles of cancer biotherapy. New York: Raven Press, 1987: 195221.
  • 7
    Morton DL, Hoon DSB, Gupta RG, Nizze AJ, Famatiga E, Foshag LJ, et al. Treatment of malignant melanoma by active specific immunotherapy in combination with biological response modifiers: In: TorisoM, YoshidaT, editors. New horizons of tumor immunotherapy. Amsterdam: Elsevier, 1989: 66583.
  • 8
    Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL. Immunogenicity of melanoma-associated gangliosjdes in cancer patients. Int J Cancer 1985; 35: 60712.
  • 9
    Livingston PO, Natoli EJ, Calves MJ, Stokert E, Oettegen HF, Old LJ. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987; 84: 29115.
  • 10
    Wallack MK, McNally KR, Leftheriotis E, Seigler H, Balch C, Wanebo H, et al. A Southeastern Cancer Study Group Phase I/II trial with vaccinia melanoma oncolysates. Cancer 1986; 57: 64955.
  • 11
    Bystryn J-C, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 1988; 61: 106570.
  • 12
    Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988; 48: 588393.
  • 13
    Hoon DSB, Foshag LJ, Nizze AJ, Bohman R, Morton DL. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 1990; 50: 535864.
  • 14
    Hayashi Y, Hoon DSB, Park MS, Terasaki PI, Foshag LJ, Morton DL. Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. Cell Immunol 1992; 139: 41125.
  • 15
    Hayashi Y, Hoon DSB, Park MS, Terasaki PI, Morton DL. Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A. Cancer Immunol Immunother 1992; 34: 41923.
  • 16
    Franco P, Boyle LA, Trentin L, Kurnick JT, Isselbacher KJ, Gattoni-Celli S. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res 1991; 51: 316470.
  • 17
    Crowley NJ, Darrow TL, Quinn-Allen MA, Seigler HF. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells: evidence for restriction by a dominant HLA-A allele. J Immunol 1991; 146: 16929.
  • 18
    Wolfel TE, Klehmann C, Muller K-H, Schutt K-H, Meyer Zum Buschenfelde, Knuth A. Lysis of human melanoma cells by autologous cytolytic T-cell clones: identification of human histo-compatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989; 170: 797810.
  • 19
    Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 1987; 78: 4554.
  • 20
    Houghton A, Eisinger M, Albino A, Cairncross J, Old L. Surface antigens of melanocytes and melanoma markers of melanocyte differentiation and melanoma subsets. J Exp Med 1982; 156: 175566.
  • 21
    Herlyn M, Koprowski H. Melanoma antigens: immunological and biological characterization and clinical significance. Annu Rev Immunol 1989; 6: 283308.
  • 22
    Hamby CV, Liao SK, Kanamuru T, Ferrone S. Immunogenicity of human melanoma-associated antigens defined by murine monoclonal antibodies in allogeneic and xenogeneic hosts. Cancer Res 1987; 47: 52849.
  • 23
    Tiwarari JL, Terasaki PI. The HLA complex. In: HLA and disease associations. New York: Springer-Verlag, 1985.
  • 24
    Friedman RJ, Rigel DS, Silverman MK, Kopf AW, Vossaert KA. Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skin. Ca 1991; 41: 2016.
  • 25
    Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 5128.
  • 26
    Jorgensen JL, Reay PA, Ehrich EW, Davis MM. Molecular components of T-cell recognition. Ann Rev Immunol 1992; 10: 83573.
  • 27
    Kourilsky P, Claverie J-M. MHC-antigen interaction: what does the T cell receptor see? Adv Immunol 1989; 45: 10793.
  • 28
    Tanaka K, Isselbacher K, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985; 228: 268.
  • 29
    Hoon DSB, Korn EL, Cochran AJ. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res 1987; 47: 17404.
  • 30
    Barbetti A, Park MS, Tersaki PI, Clark B, Fan J-L. HLA serologic epitopes: In: TerasakiP, editor. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1989: 44757.
  • 31
    Hollistead A, Elias EG, Arlen M, Buda B, Mosley M, Scherrer J. Specific activity immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigen (TAA): a Phase I clinical trial. Cancer 1985; 56: 4809.
  • 32
    Vitetta ES, Berton MT, Burger C, Kepron M, Lee WT, Yin X-M. Memory B and T cells. Annu Rev Immunol 1991; 9: 193217.
  • 33
    Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334: 395402.
  • 34
    Chen BP, Madrigal A, Parham P. Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule. J Exp Med 1990; 172: 77988.
  • 35
    Van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48: 101925.
  • 36
    Kock A, Schwarz T, Urbanski A, Peng Z, Vetterlein M, Micksche M, et al. Expression and release of interleukin-1 by different human melanoma cell lines. J Natl Cancer Inst 1989; 81: 3642.
  • 37
    Alexander MA, Bennicelli J, Guerry IV D. Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease. J Immunol 1989; 143: 40708.
  • 38
    Hoon DSB, Banez M, Okun E, Morton DL, Irie RF. Modulation of human melanoma cells by interleukin-4 and in combination with γ-interferon or α-tumor necrosis factor. Cancer Res 1991; 51: 20028.
  • 39
    Strassman G, Bach FH. OKT4+ cytotoxic T cells can lyse targets via class I molecules and can be blocked by monoclonal antibody against T molecules. J Immunol 1984; 133: 17059.
  • 40
    De Bueger M, Bakker A, Goulmy E. Existence of mature human CD4+ T cells with genuine class I restriction. Eur J Immunol 1992; 22: 8758.
  • 41
    Paliard X, de Waal Malefijt R, de Vries JE, Spits H. Interleukin-4 mediates CD8 induction on human CD4+ T cell clones. Nature 1988; 335: 6424.
  • 42
    Davytan D, Hoon DSB, Schmid I, Morton DL. Modulation of tumor infiltrating lymphocytes (TIL) in melanoma (mel) after active specific immunotherapy [abstract]. Proc Am Assoc Cancer Res 1991; 32: 252.
  • 43
    Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encloding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 16435.
  • 44
    Euhus DM, Gupta RK, Morton DL. Characterization of a 90–100 kDa tumor-associated antigen in the sera of melanoma patients. Int J Cancer 1990; 45: 106570.
  • 45
    Vlock DR, Aul DJ, Toporowicz A, McCoy JP, Brown WE. Purification and partial characterization of a shed 66 kDa melanoma-associated antigen identified by autologous antibody. Biochem Biophys Acta 1991; 1080: 110.